Immune cell interactions in tuberculosis

JAL Flynn, J Chan - Cell, 2022 - cell.com
Despite having been identified as the organism that causes tuberculosis in 1882,
Mycobacterium tuberculosis has managed to still evade our understanding of the protective …

Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment

Y Huang, X Guo, Y Wu, X Chen, L Feng, N Xie… - … and Targeted Therapy, 2024 - nature.com
Inflammation-associated diseases encompass a range of infectious diseases and non-
infectious inflammatory diseases, which continuously pose one of the most serious threats to …

Diagnosis for latent tuberculosis infection: new alternatives

C Carranza, S Pedraza-Sanchez… - Frontiers in …, 2020 - frontiersin.org
Latent tuberculosis infection (LTBI) is a subclinical mycobacterial infection defined on the
basis of cellular immune response to mycobacterial antigens. The tuberculin skin test (TST) …

Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques

K Dijkman, CC Sombroek, RAW Vervenne… - Nature medicine, 2019 - nature.com
Tuberculosis (TB) remains the deadliest infectious disease, and the widely used Bacillus
Calmette–Guérin (BCG) vaccine fails to curb the epidemic. An improved vaccination strategy …

Macrophage: a cell with many faces and functions in tuberculosis

F Ahmad, A Rani, A Alam, S Zarin, S Pandey… - Frontiers in …, 2022 - frontiersin.org
Mycobacterium tuberculosis (Mtb) is the causative agent of human tuberculosis (TB) which
primarily infects the macrophages. Nearly a quarter of the world's population is infected …

IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure

LL Lu, MT Smith, KKQ Yu, C Luedemann… - Nature medicine, 2019 - nature.com
Abstract Exposure to Mycobacterium tuberculosis (Mtb) results in heterogeneous clinical
outcomes including primary progressive tuberculosis and latent Mtb infection (LTBI). Mtb …

Latent tuberculosis: two centuries of confusion

MA Behr, E Kaufmann, J Duffin… - American journal of …, 2021 - atsjournals.org
The current dogma is that 2 billion individuals, making up a quarter of the world's population,
are latently infected with Mycobacterium tuberculosis (1–4). It is thought that latent …

Urogenital tuberculosis—epidemiology, pathogenesis and clinical features

A Muneer, B Macrae, S Krishnamoorthy… - Nature Reviews …, 2019 - nature.com
Tuberculosis (TB) is the most common cause of death from infectious disease worldwide. A
substantial proportion of patients presenting with extrapulmonary TB have urogenital TB (UG …

Key advances in vaccine development for tuberculosis—Success and challenges

R Lai, AF Ogunsola, T Rakib, SM Behar - NPJ vaccines, 2023 - nature.com
Breakthrough findings in the clinical and preclinical development of tuberculosis (TB)
vaccines have galvanized the field and suggest, for the first time since the development of …

Antimicrobial peptides grafted onto the surface of N-acetylcysteine-chitosan nanoparticles can revitalize drugs against clinical isolates of Mycobacterium tuberculosis

LMDG Primo, CA Roque-Borda, CSC Canales… - Carbohydrate …, 2024 - Elsevier
Tuberculosis is caused by Mycobacterium tuberculosis (MTB) and is the leading cause of
death from infectious diseases in the World. The search for new antituberculosis drugs is a …